Rexahn Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Rexahn Pharmaceuticals Inc.
Vanguard Total Stock Market Index Fund
697,518
2.2%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
359,304
1.12%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
103,785
0.33%
0
0%
07/31/2018
iShares Micro Cap ETF
83,727
0.26%
0
0.01%
09/06/2018
Bridgeway Ultra Small Company Market Fund
50,100
0.16%
50,100
0.02%
12/31/2017
Fidelity Spartan Total Market Index Fund
42,298
0.13%
0
0%
07/31/2018
Vanguard Institutional Total Stock Market Index Fund
29,763
0.09%
0
0%
07/31/2018
Vanguard Balanced Index Fund
11,589
0.04%
0
0%
07/31/2018
iShares Core S&P Total US Stock Market ETF
10,422
0.03%
0
0%
09/06/2018
Vanguard Total Stock Market Index Trust
8,460
0.03%
0
0%
07/31/2018
| Address |
15245 Shady Grove Road
Rockville Maryland 20850
United States
|
|
Employees
|
- |
| Website |
http://www.rexahn.com |
| Updated |
09/14/2018 |
| Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; RX-5902 or Supinoxin for metastatic triple negative breast cancer; and RX-0201 or Archexin for renal cell carcinoma, glioblastoma, ovarian, stomach, and pancreatic cancer. It also develops nano-based drug delivery systems. |
